Acetate and other short-chain fatty acids promote intestinal immune tolerance and barrier function.

The role of short-chain fatty acids (SCFAs) in intestinal health is well-documented, with acetate, propionate, and butyrate acting as critical signaling molecules that maintain the balance between immune tolerance and defensive vigilance.

Clinical and effectiveness evidence

Recent clinical evidence demonstrates that increasing systemic and colonic SCFA levels, particularly through fermentable starches like HAMSAB, shifts the human immune profile toward a more regulatory phenotype.

• Regulatory T-cells (Tregs): Research indicates that SCFAs enhance the suppressive function of Foxp3+ Tregs. In human trials, higher levels of acetate and butyrate are associated with increased production of anti-inflammatory cytokines like IL-10 and TGF-β, which are essential for suppressing overactive Th1 and Th17 immune responses.
• Barrier Integrity: SCFAs are vital for maintaining the physical gut barrier. In vitro studies using Caco-2 and T84 cells show that SCFAs significantly increase transepithelial electrical resistance (TEER) and decrease paracellular permeability, effectively "sealing" the gut against unwanted luminal antigens.

Mechanistic explanations

The influence of SCFAs on immune tolerance and barrier function occurs through specific molecular pathways:

• Receptor Signaling: Acetate primarily signals through the G-protein coupled receptor GPR43 (FFAR2). This signaling in dendritic cells and intestinal epithelial cells reduces pro-inflammatory IL-6 and IL-12 production, creating a tolerogenic environment.
• Transcriptional Regulation: Butyrate and, to a lesser extent, acetate act as histone deacetylase (HDAC) inhibitors. This allows for the transcriptional upregulation of sealing tight junction proteins, such as claudin-1 and occludin, which physically strengthen the epithelial barrier.
• IgA Production: Acetate supports B-cell metabolism and differentiation into IgA-producing plasma cells via GPR43. Under normal conditions, this promotes "homeostatic" IgA that coats commensal bacteria to maintain peace in the gut.

Implications of low SCFAs

When SCFA levels are low, the gut loses these stabilizing signals, leading to potential immune dysregulation:

• Immune Hypervigilance: Low SCFAs weaken the epithelial barrier and reduce Treg activity, allowing more microbial antigens to penetrate the tissue. This triggers a shift toward "hypervigilance," where the immune system compensates with inflammatory responses and systemic IgG production.
• Secretory IgA (sIgA) Dynamics: While SCFAs generally promote sIgA production, a deficiency does not always result in lower sIgA. In states of low SCFA availability, the body may produce compensatory, high-affinity sIgA or experience a paradoxical increase in pathogenic IgA as the immune system reacts to the loss of barrier integrity and mucosal tolerance.

Bottom line

Strong evidence supports that SCFAs, especially acetate, promote immune tolerance through Treg induction and barrier fortification. While low SCFAs shift the gut toward a state of immune hypervigilance, the effect on sIgA is complex and context-dependent, often representing a compensatory or pathological response rather than a simple decrease.